Proteolytic activation defines distinct lymphangiogenic mechanisms for VEGFC and VEGFD
The Journal of clinical investigation, 2016-06, Vol.126 (6), p.2167-2180 [Peer Reviewed Journal]COPYRIGHT 2016 American Society for Clinical Investigation ;COPYRIGHT 2016 American Society for Clinical Investigation ;Copyright American Society for Clinical Investigation Jun 2016 ;Copyright © 2016, American Society for Clinical Investigation 2016 American Society for Clinical Investigation ;ISSN: 0021-9738 ;EISSN: 1558-8238 ;DOI: 10.1172/jci83967 ;PMID: 27159393
Full text available